Among these, secukinumab, a fully human IL-17A monoclonal antibody, has been sanctioned for the management of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, among other conditions. The gene discussed is IL17A; the disease is psoriasis vulgaris.